-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, UCB announced that the European Commission has approved the company's development of Bimzelx (bimekizumab) for the treatment of patients with moderate to severe plaque psoriasis suitable for systemic treatment
.
The press release states that this is the first IL-17A/IL-17F inhibitor approved for the treatment of psoriasis
The fully humanized monoclonal antibody bimekizumab can strongly and specifically neutralize IL-17A and IL-17F
.
IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis
▲Schematic diagram of the working mechanism of Bimekizumab (picture source: reference [2])
This approval was supported by three phase 3 clinical trials BE VIVID, BE READY and BE SURE, involving 1,480 patients with moderate to severe psoriasis
.
All studies reached the common primary endpoint and critical secondary endpoint of the trial
(The original text has been deleted)
Reference materials:
Reference materials:[1] UCB Announces European Commission Approval of BIMZELX[®]▼ (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.
[1] UCB Announces European Commission Approval of BIMZELX[®]▼ (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.